natgillin/translations-raw huggingface dataset:
The results of this study show a clear positive effect of toremifene in the 80 mg group with mean prolongations of 21 - 26 ms.
Rezultati te študije kažejo jasen pozitivni učinek učinkovine toremifen v skupini, v kateri so bolniki prejemali 80 mg zdravila in pri katerih je znašalo povprečno podaljšanje intervala od 21–26 ms.
the results of your blood tests (these will be carried out before your treatment starts) the disease you are being treated for
vaših izvidov krvnih preiskav (ki bodo opravljene pred začetkom zdravljenja), bolezni, zaradi katere se zdravite.
The results presented below represent the intent-to-treat population studied in MDS-003 and MDS-004; with the results in the isolated Del (5q) sub-population also shown separately (see section 4.1 for the approved indication).
Rezultati, predstavljeni v nadaljevanju, predstavljajo populacijo, namenjeno za zdravljenje, ki so jo proučevali v MDS-003 in MDS-004; rezultati podskupine z izolirano nepravilnostjo del(5q) pa so prikazani tudi ločeno (za odobrene indikacije glejte poglavje 4.1).
The results show that a higher percentage of post-surgical adults experienced complete response (no emesis and no use of rescue) with aprepitant 40 mg than with ondansetron 4 mg (lower bound of C.I. is 0.0 indicating borderline significance) as described in Table 1.
Rezultati, prikazani v preglednici 1 kažejo, da je imelo popoln odziv (brez bruhanja in brez rešilnega zdravljenja) večji odstotek post-operativnih odraslih v skupini, ki je prejemala aprepitant 40 mg, kot v skupini, ki je prejemala ondansetron 4 mg (spodnja meja intervala zaupanja (IZ) je 0,0 kar kaže na mejno signifikantnost):
The results showed a similar incidence of combined neuropsychiatric adverse events, other than sleep disorders, in patients treated with varenicline compared to patients treated with placebo, with a risk ratio (RR) of 1.01 (95% CI: 0.89-1.15).
Rezultati so pri bolnikih, zdravljenih z vareniklinom, in bolnikih, zdravljenih s placebom, pokazali podobno pojavnost kombiniranih nevropsihiatričnih neželenih učinkov, ki ne vključujejo motenj spanja, pri čemer je bilo razmerje tveganja (RR) 1,01 (95 % IZ: 0,89–1,15).
The results showed no effect of oritavancin on S- warfarin AUC and Cmax.
Rezultati niso pokazali nobenega učinka oritavancina na vrednosti AUC in Cmax S- varfarina.
The results showed no increase in the incidence of suicidal ideation and/or behaviour in patients treated with varenicline compared to patients treated with placebo, as shown in the table below.
Rezultati niso pokazali povečanja incidence samomorilnih misli in/ali vedenja pri bolnikih, zdravljenih z vareniklinom, v primerjavi z bolniki, zdravljenimi s placebom, kot je prikazano v spodnji preglednici.
The results showed no significant difference in the pharmacokinetics of bevacizumab in relation to age.
Rezultati so pokazali, da ni značilnih razlik v farmakokinetiki bevacuzimaba glede na starost.
The results showed no significant difference in the PK of siltuximab in patients older than 65 years compared to patients age 65 years or younger.
Rezultati niso pokazali bistvene razlike v farmakokinetiki siltuksimaba pri bolnikih, starejših od 65 let v primerjavi z bolniki starimi 65 let ali manj.
The results showed that developmental changes of aliskiren exposure correlated with the ontogeny of transporter maturation in jejunum, liver, kidney and brain.
Rezultati študije kažejo, da razvojne spremembe izpostavljenosti aliskirenu korelirajo z ontogenetskim dozorevanjem prenašalcev v jejunumu, jetrih, ledvicah in možganih.
The results showed that there was a mean increase of 1.89 fold [1.32; 2.70] in the abacavir AUC, and 1.58 [1.22; 2.04] fold in the elimination half-life.
Rezultati so pokazali, da je bila AUC abakavirja povečana v povprečju za 1,89-krat [1,32; 2,70], eliminacijski razpolovni čas pa v povprečju za 1,58-krat [1,22; 2,04].
The results suggest that the lipid components undergo hydrolysis and are largely incorporated in the tissues following breakdown in the intrathecal space.
Ti rezultati kažejo na to, da pride pri lipidnih komponentah do hidrolize in da se te po razpadu v intratekalem prostoru v veliki meri vgradijo v tkiva.
The results were also calculated separately between ‘HBeAg-positive’ patients (infected with the common hepatitis B virus) and ‘HBeAg-negative’ patients (infected with a virus that has mutated, leading to a form of chronic hepatitis B that is more difficult to treat).
Rezultati so bili izračunani tudi ločeno za bolnike, ki so bili „HBeAg pozitivni“ (okuženi z običajnim virusom hepatitisa B), in za bolnike, ki so bili „HBeAg negativni“ (okuženi z virusom, ki je mutiral, kar je privedlo do oblike kroničnega hepatitisa B, ki jo je težje zdraviti).
The results were lower than the results obtained in the pivotal trial: a sensitivity range between 77.5% to 90% and specificity range between 62.5-85.7%.
Ti rezultati so imeli manjše vrednosti kot rezultati, dobljeni v ključni študiji: razpon občutljivosti med 77,5 % in 90 % ter razpon specifičnosti
The results were measured using the Genant-modified total Sharp score (TSS) and its components, the erosion score and joint space narrowing (JSN) score.
Rezultate so vrednotili na osnovi skupne Sharpove ocene, modificirane po Genantu (TSS-Genant-modified total Sharp score) in njenih komponent, ocene erozije in ocene zožitve sklepne špranje (JSN-joint space narrowing).
The results were similar in those who had and those who had not taken systemic treatments for psoriasis before.
Rezultati so bili pri bolnikih, ki so predhodno prejemali sistemska zdravila za psoriazo, podobni kot pri bolnikih, ki teh zdravil niso prejemali.
The results were similar to those for the ANORO dose and provided additional supportive evidence for the efficacy of ANORO.
Rezultati so bili podobni rezultatom z odmerkom v zdravilu ANORO in dodatno potrjujejo učinkovitost zdravila ANORO.
The results were similar to those for the LAVENTAIR dose and provided additional supportive evidence for the efficacy of LAVENTAIR.
Rezultati so bili podobni rezultatom z odmerkom v zdravilu LAVENTAIR in dodatno potrjujejo učinkovitost zdravila LAVENTAIR.
The results will be compared and a significant increase in the amount of carbon-13 in the second set of samples will suggest to your doctor that Helicobacter pylori is present.
Rezultate bodo primerjali in znatno povečanje količine ogljika-13 v drugem vzorcu bo pomenilo veliko verjetnost prisotnosti Helicobacter pylori.
The results with pitolisant were significantly superior to those in the placebo group (mean difference: -3.33; 95%CI [-5.83 to -0.83]; p < 0.05) but did not differ significantly from the results in the modafinil group (mean difference: 0.12; 95%CI [-2.5 to 2.7]).
Rezultati v skupini s pitolizantom so bili znatno boljši kot v skupini s placebom (povprečna razlika: –3,33; 95-odstotni IZ [–5,83 do –0,83]; p < 0,05), niso pa se bistveno razlikovali od rezultatov v skupini z modafinilom (povprečna razlika: 0,12; 95-% IZ [–2,5 do 2,7]).
The reversibility of growth inhibition is uncertain.
Ni gotovo, da bo omenjena zavora rasti reverzibilna.
The REYATAZ/ritonavir arm showed similar (non-inferior) antiviral efficacy compared to the lopinavir/ritonavir arm, as assessed by the proportion of patients with HIV RNA < 50 copies/ml at week 48 (Table 5).
V skupini, ki je prejemala zdravilo REYATAZ/ritonavir, je bila protivirusna učinkovitost podobna (ni bila manjša) kot v skupini, ki je prejemala lopinavir/ritonavir, kar je bilo ovrednoteno z deležem bolnikov z vrednostjo HIV RNA < 50 kopij/ml v 48. tednu (preglednica 5).
The ribavirin dose was weight-based at
Odmerek ribavirina je bil določen na podlagi telesne mase in je znašal
The rinse should not be swallowed.
Izpiralne tekočine ne smete pogoltniti.
The risk appears to be higher when fibrin sealants are sprayed with air, as compared to CO2 and therefore cannot be excluded with Raplixa.
Kaže, da je tveganje večje, pri pršenju fibrinskih lepil z zrakom v primerjavi s CO2, zato ga pri uporabi zdravila Raplixa ni mogoče izključiti.
The risk for abacavir HSR to occur is high for patients who test positive for the HLA-B*5701 allele.
Tveganje za pojav HSR na abakavir je visoko pri bolnikih, ki so imeli pozitiven test za alel HLA- B*5701.
The risk for development of NSF in patients with moderate renal impairment (GFR 30–59 ml/min/1.73 m2) is unknown; therefore, Optimark should only be used after careful risk-benefit evaluation in patients with moderate renal impairment.
Tveganje za razvoj NSF pri bolnikih z zmerno ledvično okvaro (GFR 30–59 ml/min/1,73 m2) ni znano, zato je uporaba zdravila Optimark pri bolnikih z zmerno okvaro ledvic dovoljena le po skrbni oceni razmerja med tveganjem in koristmi.
The risk for development of NSF in patients with moderate renal impairment (GFR 30–59 ml/min/1.73 m²) is unknown; therefore Optimark should only be used after careful risk-benefit evaluation in patients with moderate renal impairment.
Tveganje za nastanek NSF pri bolnikih z zmerno okvaro ledvic (GFR 30-59 ml/min/1,73 m2) ni znano; zato je treba zdravilo Optimark pri bolnikih z zmerno okvaro ledvic uporabljati le po skrbni analizi koristi in tveganj.
The risk for development of NSF in patients with moderate renal impairment (GFR 30–59 ml/min/1.73 m²) is unknown; therefore, Optimark should only be used after careful risk-benefit evaluation in patients with moderate renal impairment.
Tveganje za razvoj NSF pri bolnikih z zmerno ledvično okvaro (GFR 30-59 ml/min/1,73 m2) ni znano, zato je uporaba zdravila Optimark pri bolnikih z zmerno okvaro ledvic dovoljena le po skrbni oceni razmerja med tveganjem in koristmi.
The risk increases over time and was about 2% after two years and about 4% after three years.
Tveganje se je s časom povečalo in je bilo približno 2 % po dveh letih in približno 4 % po treh letih.
The risk is particularly high in combination with potassium sparing-diuretics and when combined with salt substitutes containing potassium.
Tveganje je posebno veliko v kombinaciji z diuretiki, ki varčujejo s kalijem, in v kombinaciji z nadomestki soli, ki vsebujejo kalij.
The risk may be increased as the trough sirolimus level increases.
Tveganje se lahko poveča z zvišanjem najnižje koncentracije sirolimusa.
The risk may increase in case of treatment combination with other medicinal products that may also provoke hyperkalaemia (salt substitutes containing potassium, potassium- sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, non steroidal anti-inflammatory medicinal products (NSAIDs, including selective COX-2 inhibitors), heparin, immunosuppressives (cyclosporin or tacrolimus), and trimethoprim).
Tveganje je lahko povečano pri kombiniranem zdravljenju z drugimi zdravili, ki lahko povzročijo hiperkaliemijo (nadomestki soli s kalijem, diuretiki, ki zadržujejo kalij, zaviralci ACE, antagonisti receptorjev angiotenzina II, nesteroidna protivnetna zdravila (tudi selektivni zaviralci ciklooksigenaze 2), heparin, imunosupresivi (ciklosporin ali takrolimus) in trimetoprim).
The risk may increase in case of treatment combination with other medicinal products that may also provoke hyperkalaemia (salt substitutes containing potassium, potassium- sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, non steroidal antiinflammatory medicinal products (NSAIDs, including selective COX-2 inhibitors), heparin, immunosuppressives (cyclosporin or tacrolimus), and trimethoprim).
Tveganje je lahko povečano pri kombiniranem zdravljenju z drugimi zdravili, ki lahko povzročijo hiperkaliemijo (nadomestki soli s kalijem, diuretiki, ki zadržujejo kalij, zaviralci ACE, antagonisti receptorjev angiotenzina II, nesteroidna protivnetna zdravila (tudi selektivni zaviralci ciklooksigenaze 2), heparin, imunosupresivi (ciklosporin ali takrolimus) in trimetoprim).
The risk may increase in case of treatment combination with other medicinal products that may also provoke hyperkalaemia (salt substitutes containing potassium, potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, non steroidal anti- inflammatory drugs (NSAIDs, including selective COX-2 inhibitors), heparin, immunosuppressives (cyclosporin or tacrolimus), and trimethoprim).
Tveganje je lahko povečano pri kombiniranem zdravljenju z drugimi zdravili, ki lahko povzročijo hiperkaliemijo (nadomestki soli s kalijem, diuretiki, ki zadržujejo kalij, zaviralci ACE, antagonisti receptorjev angiotenzina II, nesteroidna protivnetna zdravila (tudi selektivni zaviralci ciklooksigenaze 2), heparin, imunosupresivi (ciklosporin ali takrolimus) in trimetoprim).
The risk may increase in case of treatment combination with other medicinal products that may also provoke hyperkalaemia (salt substitutes containing potassium, potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, non steroidal anti- inflammatory medicinal products (NSAIDs, including selective COX-2 inhibitors), heparin, immunosuppressives (cyclosporin or tacrolimus), and trimethoprim).
Tveganje je lahko povečano pri kombiniranem zdravljenju z drugimi zdravili, ki lahko povzročijo hiperkaliemijo (nadomestki soli s kalijem, diuretiki, ki zadržujejo kalij, zaviralci ACE, antagonisti receptorjev angiotenzina II, nesteroidna protivnetna zdravila (tudi selektivni zaviralci ciklooksigenaze 2), heparin, imunosupresivi (ciklosporin ali takrolimus) in trimetoprim).
The risk may increase in case of treatment combination with other medicinal products that may also provoke hyperkalaemia (salt substitutes containing potassium, potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, non steroidal anti- inflammatory medicinal products (NSAIDs, including selective COX-2 inhibitors), heparin, immunosuppressives (cyclosporin or tacrolimus), and trimethoprim).
Tveganje je lahko povečano pri kombiniranem zdravljenju z drugimi zdravili, ki lahko povzročijo hiperkaliemijo (nadomestki soli s kalijem, diuretiki, ki zadržujejo kalij, zaviralci ACE, antagonisti receptorjev angiotenzina II, nesteroidna protivnetna zdravila (tudi selektivni zaviralci ciklooksigenaze 2), heparin; imunosupresivi (ciklosporin ali takrolimus) in trimetoprim).
The risk may increase in case of treatment combination with other medicinal products that may also provoke hyperkalaemia (salt substitutes containing potassium, potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, non steroidal anti- inflammatory medicinal products (NSAIDs, including selective COX-2 inhibitors), heparin, immunosuppressives (cyclosporin or tacrolimus), and trimethoprim).
Tveganje je lahko povečano pri kombiniranem zdravljenju z drugimi zdravili, ki lahko povzročijo hiperkaliemijo (nadomestki soli s kalijem, diuretiki, ki zadržujejo kalij, zaviralci ACE, antagonisti receptorjev angiotenzina II, nesteroidna protivnetna zdravila /tudi selektivni zaviralci ciklooksigenaze 2/, heparin, imunosupresivi /ciklosporin ali takrolimus/ in trimetoprim).
The risk may increase in case of treatment combination with other medicinal products that may also provoke hyperkalaemia (salt substitutes containing potassium, potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, non steroidal anti- inflammatory medicinal products (NSAIDs, including selective COX-2 inhibitors), heparin, immunosuppressives (cyclosporin or tacrolimus), and trimethoprim).
Tveganje se lahko poveča med kombiniranim zdravljenjem z drugimi zdravili, ki prav tako povzročijo hiperkaliemijo (nadomestkov soli, ki vsebujejo kalij, diuretikov, ki varčujejo s kalijem, zaviralcev ACE, antagonistov receptorjev angiotenzina II, nesteroidnih protivnetnih zdravil (NSAID, vključno s selektivnimi zaviralci COX-2), heparina, imunosupresivov (ciklosporin ali takrolimus) ali trimetoprima).
The risk of a blood clot with EVRA is small but some conditions will increase the risk.
Tveganje krvnega strdka z zdravilom [izmišljeno ime] je majhno, vendar nekatera stanja tveganje povečajo.
The risk of a blood clot with IOA is small but some conditions will increase the risk.
Tveganje za nastanek krvnega strdka je z zdravilom IOA majhno, vendar pa nekatera stanja to tveganje povečajo.
The risk of a blood clot with Zoely is small but some conditions will increase the risk.
Tveganje za nastanek krvnega strdka je z zdravilom Zoely majhno, vendar pa nekatera stanja to tveganje povečajo.
The risk of a further decrease in atazanavir exposure is expected when atazanavir is given with medicinal products known to reduce its exposure (e.g., tenofovir disoproxil fumarate or H2-receptor antagonists).
Nadaljnje zmanjšanje izpostavljenosti atazanavirju se lahko pričakuje, kadar se atazanavir daje skupaj z zdravili, za katera je znano, da zmanjšajo izpostavljenost atazanavirju (npr. dizoproksiltenofovirat fumarat ali antagonisti receptorjev H2).
The risk of a further decrease in atazanavir exposure is expected when atazanavir is given with medicinal products known to reduce its exposure (e.g., tenofovir or H2-receptor antagonists).
Nadaljnje zmanjšanje izpostavljenosti atazanavirju se lahko pričakuje, kadar se atazanavir daje skupaj z zdravili, za katera je znano, da zmanjšajo izpostavljenost atazanavirju (npr. tenofovir ali antagonisti receptorjev H2).
The risk of a potential interaction between NovoSeven and coagulation factor concentrates is unknown.
Tveganje za možne interakcije med zdravilom NovoSeven in koncentrati koagulacijskih faktorjev ni znano.
The risk of a second clinical attack over 2 years was 35.9% in the placebo group and 24.0% in the teriflunomide 14 mg treatment group (hazard ratio: 0.57, 95% confidence interval: 0.38 to 0.87, p=0.0087).
Tveganje za drugi klinični napad je bilo v 2- letnem obdobju v skupini s placebom 35,9 % in v skupini s 14 mg teriflunomida 24,0 % (razmerje ogroženosti: 0,57, 95 % interval zaupanja: od 0,38 do 0,87, p = 0,0087).
The risk of a thromboembolic event was greatest in the first four months of therapy.
Tveganje za tromboembolične zaplete je bilo največje v prvih štirih mesecih terapije.
The risk of abrupt discontinuation of INOmax therapy in the event of critical failure of the delivery system and how to prevent it
Tveganje nenadne prekinitve zdravljenja z zdravilom INOmax v primeru kritične odpovedi sistema za dovajanje in kako to preprečiti.
The risk of acute hypersensitivity reactions (including anaphylactic shock) and delayed hypersensitivity reactions.
Tveganje za akutne preobčutljivostne reakcije (vključno z anafilaktičnim šokom) in pozne preobčutljivostne reakcije.
The risk of acute hypersensitivity reactions (including anaphylactic shock) and delayed hypersensitivity reactions.
tveganjem za pojav akutnih preobčutljivostnih reakcij (vključno z anafilaktičnim šokom) in zapoznelih preobčutljivostnih reakcij,
The risk of acute injection-related reactions and delayed serious systemic hypersensitivity reactions, the need for instructing patients on techniques for administration, and guidance for Health Care Professionals on how to report administration errors,
Tveganje za akutne reakcije, povezane z injiciranjem in zakasnjene resne sistemske preobčutljivostne reakcije, potreba po izobraževanju bolnikov o načinu uporabe in navodila strokovnjakom z zdravstvenega področja glede poročanja o napakah pri uporabi
The risk of acute injection-related reactions;
o tveganju akutnih reakcij, povezanih z okužbami;
The risk of additional systemic toxicity should be considered when large doses of Fortacin are applied to patients already using other local anaesthetics or structurally related medicinal products e.g. class I anti-arrhythmics such as mexiletine.
Pri nanosu večjih količin zdravila Fortacin pri bolnikih, ki že uporabljajo druge lokalne anestetike ali strukturno povezana zdravila, npr. antiaritmike razreda I kot meksiletin, je treba upoštevati tveganje za dodatno sistemsko toksičnost.
The risk of agranulocytosis and neutropenia is higher if the baseline absolute neutrophil count (ANC) is less than 1.5x109/l.
Nevarnost agranulocitoze in nevtropenije je višja, če je osnovno absolutno nevtrofilno število (ANC) manjše od 1,5 x 109/l.
The risk of allergic reaction and of cross reactivity and the contraindication in patients allergic to pineapple and papain or to previous application of the product
Tveganje o alergijskih reakcijah in navzkrižnih reakcijah ali kontraindikacijah pri bolnikih, alergičnih na ananas in papain ali na prejšnji nanos zdravila
the risk of anaphylaxis and of severe allergic reactions and the measures necessary to minimise it:
tveganje anafilakse in resnih alergijskih reakcij ter ukrepe, ki so potrebni za njihovo zmanjšanje:
The risk of Avastin-associated hypertension did not correlate with the patients’ baseline characteristics, underlying disease or concomitant therapy.
Tveganje za pojav hipertenzije ob zdravljenju z zdravilom Avastin ni bilo povezano z osnovnimi značilnostmi bolnikov, spremljajočimi obolenji ali ostalo terapijo, ki so jo prejemali.
The risk of birth defect is increased by factor 2 to 3 in the offspring of mothers treated with an antiepileptic medicinal product.
Pri otrocih mater, zdravljenih z antiepileptičnim zdravilom, se tveganje prirojene okvare zveča za dvakrat do trikrat.
The risk of birth defect is increased by factor 2 to 3 in the offspring of mothers treated with an antiepileptic medicinal product.
Pri otrocih mater, zdravljenih z antiepileptičnim zdravilom, se tveganje za prirojene okvare zveča za dvakrat do trikrat.
The risk of bladder cancer and relevant risk minimisation advice.
Tveganje za nastanek raka mehurja in ustrezen nasvet za zmanjšanje tveganja.
The risk of bladder cancer and relevant risk minimisation advice.
tveganje za nastanek raka mehurja ter ustrezne nasvete za zmanjševanje tveganja
The risk of bladder cancer and relevant risk minimisation advice.
tveganje za nastanek raka sečnega mehurja in ustrezen nasvet za zmanjšanje tveganja.
The risk of bladder cancer and relevant risk minimisation advice.
Tveganju za raka sečnega mehurja in ustreznim nasvetom za zmanjšanje tega tveganja.
The risk of bladder cancer risk and relevant risk minimisation advice.
Tveganje za nastanek raka mehurja in ustrezen nasvet za zmanjšanje tveganja.
The risk of bleeding (life-threatening, major, minor, other) decreased during the course of the trial: 0-1 months (clopidogrel: 9.6%; placebo: 6.6%), 1-3 months (clopidogrel: 4.5%; placebo: 2.3%), 3-6 months (clopidogrel: 3.8%; placebo: 1.6%),
Tveganje za krvavitev (življenje ogrožajoče, velike, manjše, druge) se je zmanjševalo tekom preskušanja: 0-1 mesec (klopidogrel: 9,6 %; placebo: 6,6 %), 1-3 meseci (klopidogrel: 4,5 %; placebo: 2,3 %), 3-6 mesecev
The risk of blood clotting may also be increased if you:
Vaše tveganje krvnih strdkov je lahko večje tudi:
The risk of cardiac adverse drug reactions appears higher in paediatric patients with previous exposure to cardiac radiation and anthracycline, compared to those paediatric patients without previous exposure.
Tveganje za pojav s srcem povezanih neželenih učinkov zdravila je večje pri pediatričnih bolnikih s predhodno izpostavljenostjo obsevanju srca in antraciklinu, v primerjavi s pediatričnimi bolniki brez predhodne izpostavljenosti.
the risk of central nervous system demyelination
tveganja za demielinizacijo osrednjega živčnega sistema,
The risk of certain side effects is greater with the 100 mg dose compared with the 50 mg dose.
Tveganje za določene neželene učinke je večje pri odmerku 100 mg v primerjavi z odmerkom 50 mg.
The risk of Congestive Heart Failure (CHF)
Tveganje za kongestivno srčno odpoved
The risk of developing a new gouty arthritis attack was also reduced with Ilaris (17% with Ilaris versus 37% with triamcinolone acetonide).
Tveganje za ponovni napad protina je bilo nižje ob jemanju zdravila Ilaris (17 % z zdravilom Ilaris v primerjavi s 37 % pri jemanju triamcinolon acetonida).
The risk of developing antibodies to eculizumab.
obstaja tveganje za nastanek protiteles proti ekulizumabu,